Background: The randomized, LEADERS FREE trial showed superior safety and efficacy of a polymer-free DCS vs. a bare metal stent in high-bleeding risk patients with only one month dual antiplatelet treatment. We report characteristics and outcomes of the pre-specified group of elderly patients (aged ≥75). Methods: Age N75 was one of the trial's inclusion criteria. The main additional criteria were: need for oral anticoagulants, recent bleeding, anemia, chronic renal failure and cancer. All patients received 1 month DAPT only. Both primary endpoints (efficacy: clinically driven TLR and safety: composite of cardiac death, MI and stent thrombosis) as well as bleeding were recorded up to 390 days. Results: 1564 elderly patients (63.4% of the population) were enrolled with a mean of 2 inclusion criteria/patient. The primary safety endpoint was reached less frequently in DCS than BMS patients (10.7 vs. 14.3%, p = 0.03), as was the primary efficacy endpoint (5.8 vs. 10.8% p = 0.0003). Major bleeding rates were high and similar in both groups (7.3 vs. 8.2%, p = 0.55). For the 562 (23.4%) patients with age as sole entry criterion, trends were similar for DCS and BMS patients respectively: safety endpoint (7.3%vs.11.4% p = 0.10) and Cd TLR (4.7 vs. 13.2% p = 0.0003), but for both groups, major bleeding occurred less frequently than for elderly patients with more comorbid conditions (3.6%vs. 2.8%). Conclusion: Compared to a BMS, use of a DCS together with a short one-month DAPT course was associated with significant safety and efficacy benefits for the elderly patients enrolled in LEADERS FREE.
Introduction
Although the age threshold defining the elderly may vary, ranging from those over 65 to octogenarians or even nonagenarians, the most frequent old age cut-off point in guidelines and clinical trials is 75 [1] [2] [3] [4] [5] . Owing to longer life expectancy, this elderly population is increasing and cardiovascular disease is its main cause of death [6, 7] .
The elderly have historically a lower PCI procedural success rate because of associated comorbidities and challenging anatomies. They are deemed at higher risk of bleeding and mortality, and the logistics of their follow-up may be difficult to organise. Physicians are less inclined to enroll them in clinical trials, and they are thus under-represented [7, 1, [8] [9] [10] [11] [12] [13] [14] . Consequently, guidelines and scientific statements [1, 2, 7, 15, 16, 17] tend to be less specific regarding the management of elderly patients with coronary disease than for younger populations. It has been repeatedly emphasized that management of this growing segment of the population requires special attention in order to ensure that all potential unmet needs are appropriately addressed [1, 8] .
The LEADERS FREE trial [18, 19] was a double-blinded randomized trial designed to compare the outcome of patients at high bleeding risk (HBR) treated with either a polymer-free BA9 drug-coated stent (DCS) or a bare metal stent (BMS) and with one-month dual antiplatelet therapy (DAPT), followed by long-term single antiplatelet therapy. Any other anti-thrombotic medication was left to the discretion of the investigator. The trial demonstrated that patients treated with BA9 DCS had superior outcomes for both the primary safety endpoint (cumulative incidence of a composite of cardiac death, myocardial infarction, or definite or probable stent thrombosis) and the primary efficacy endpoints (clinically driven target lesion revascularization [cd TLR]). We report here the characteristics and outcomes of the pre-specified group of elderly patients (aged ≥ 75). In addition, we analyzed the subset of patients whose age was their sole inclusion criterion and finally compared the baseline characteristics and outcomes of older and younger patients included in the trial.
Methods

Design and methods
Patients and methods
All patients from the LEADERS FREE trial aged 75 or more who completed follow-up were included in this analysis. The methods of the LEADERS FREE double-blinded randomized trial have been described previously [18, 19] . In short, 2466 high bleeding risk patients were enrolled by 68 sites in 20 countries. The most frequent inclusion criteria were age ≥75, oral anticoagulant treatment, recent bleeding, anemia, and co-morbid conditions such as chronic renal failure or cancer.
Patients were randomly assigned in a 1:1 ratio to undergo PCI with a polymer-free BA9-coated stent or a similar bare-metal stent (BioFreedom and Gazelle stent, Biosensors Europe, SA). All patients received 1 month of DAPT. Patient visits were performed at 30 days and 1 year and telephone contact at 2 and 4 months. Both primary endpoints (efficacy: clinically driven TLR and safety: composite of cardiac death, MI and stent thrombosis) as well as bleeding according to the Bleeding Academic Research Consortium (BARC) [20] were recorded up to 390 days.
Study proceedings
PCI was performed using standard techniques. All target lesions were treated with at least one study stent. Staged procedures were permitted within 1 week of the index procedure.
Statistical analysis
Continuous variables are presented as mean ± SD, and categorical data as counts and percentages. For comparing characteristics on patient level for continuous variables a 2 sample t-test was used. Categorical variables were compared using a chi-square test. Whenever appropriate a Fisher exact test was used instead.
Due to the nature of the data, (time to event variables) and the objective of this analysis (comparison of DCS vs. BMS outcomes in elderly patients) survival methods were used. Hazard ratios and their 95% confidence intervals were derived from an unadjusted Cox proportional hazard model. Cumulative incidence rates are based on the KaplanMeier estimator with log-rank p-value to test if the plots differ over time. The proportional hazards assumptions were checked using Schoenfeld residuals. For statistical models including stent group and age categories as covariates, an interaction variable was also entered in the model to evaluate the relationship between those two variables. Statistical significance of the interaction term was evaluated via a likelihood ratio test.
All available data were used in the analysis of all endpoints. All data were analyzed using SAS V.9.3 (SAS Institute, Cary, North Carolina, USA).
Results
Baseline and procedural characteristics of elderly patients
In total, 1564 patients (789 recipients of DCS and 775 of BMS) included in the LEADERS FREE trial were aged 75 or older, representing 63.4% of the overall trial population.
There were a mean of 2 entry criteria per patient, and the most frequently used inclusion criteria in addition to advanced age were oral anticoagulant treatment (30.9%), chronic renal failure (21.4%), anemia (14.4%), planned surgery (11.0%) and cancer (7.4%). The baseline characteristics were not significantly different between patients receiving a DCS or a BMS. The mean age of the patients was 81.3 ± 4.3 and 36.3% were women. Atrial fibrillation was present in 33.2% of the study population and the procedure was carried out via the radial approach in 59.3% (Table 1) . During the procedure, Bivalirudin was used for 1.3% and GP IIb/IIIa blockers for 1.1% of patients. At discharge, 96.8% of patients were on DAPT (including 93.6% on clopidogrel, 4.9% on ticagrelor and 0.8% on prasugrel), and oral anticoagulants were prescribed for 31.4% of patients. No significant differences in anti-thrombotic medication were observed between the DCS and the BMS groups.
Primary safety and efficacy endpoints
Both the primary safety (composite of cardiac death, myocardial infarction and stent thrombosis) and efficacy (incidence of clinically driven TLR) endpoints occurred less frequently in patients treated with DCS compared to BMS: safety: (10.7% vs. 14.3%, HR: 0.73, 95% CI 0.55 to 0.97, p = 0.03), efficacy (5.8 vs. 10.8%, HR: 0.51, 95% CI 0.35 to 0.74, p = 0.0003) (Fig. 1A & B) . The major (BARC 3 to 5) bleeding rate was similar in DCS and BMS recipients (7.3 vs. 8.2%, p = 0.55). (Table 1 ).
Subgroup of patients with age ≥75 as the sole inclusion criterion
For the 562 (23.4%) patients with age as the sole entry criterion, trends for superiority of DCS were similar for primary safety endpoint (7.3 vs. 11.4% p = 0.10) cardiac death (1.3 vs. 2.4% p = 0.36), MI (6.6 vs. 9.9%, p = 0.17) and stent thrombosis (0.7 vs. 2.4% p = 0.09) for DCS and BMS respectively. For the efficacy endpoint (cd TLR) a significant benefit was associated with DCS vs. BMS (4.7 vs. 13.2% p = 0.0003). Major bleeding rates were similar in both arms (3.6 vs. 2.8%, p = 0.54) (see Supplementary Table) .
Comparison between older and younger LEADERS FREE patients
When taking both stent groups into consideration and evaluating baseline and procedural characteristics according to age, (≥75 vs. b75) ( Table 2) , the elderly comprised a significantly higher percentage of women (36.3 vs. 19.6, p b 0.001) while the incidence of diabetes (29.6% vs. 39.7% p b 0.01) and hypercholesterolemia (59.6% vs.
67.3% p = 0.0001) was lower. The elderly also had a higher rate of multivessel disease (63.8% vs. 59.5% p = 0.0024), presented more often with STEMI/NSTEMI and their CRUSADE bleeding score was higher (37.1 vs. 29.4, p b 0.001). Procedural characteristics were comparable to those of the younger population but procedural success (successful treatment of all target lesions without the occurrence of death, MI, or TVR during the hospital stay) was lower (95.4 versus 97.2% p: 0.02).
Combining both stent groups, the primary safety endpoint [composite of death, MI and stent thrombosis] was reached more often in patients ≥75 (12.5 vs. 8.7% p = 0.003), as was the primary efficacy endpoint [clinically indicated TLR] (8.2 vs. 6.0% p = 0.04), while the BARC 3-5 bleeding rates were similar in older and younger HBR patients (7.7 vs. 6.3%, p = 0.17). Superiority of DCS over BMS was maintained regardless of the age group ( Fig. 2A & B) .
Discussion
The present study focused on the outcomes of the predefined subgroup of patients aged 75 or over who accounted for 63% of the LEADERS FREE Trial population. The main findings are that 1) this high-risk population treated with one month DAPT only, derived an important and significant benefit from DCS treatment over BMS both in terms of safety and efficacy (Fig. 1A & B) . 2) While most elderly patients had several HBR inclusion criteria (mean of 2 per patient), those enrolled only because of age also benefited significantly in terms of efficacy and showed a non-significant but favorable consistent trend for all components of the safety endpoint. 3) Compared to younger HBR patients, the elderly differed for several baseline characteristics. While the benefit of DCS over BMS was maintained, the event rates for both safety and efficacy endpoints were higher for both stent groups in the elderly patients ( Fig. 2A & B) .
The present study constitutes the largest randomized evaluation of elderly patients treated with PCI [3, 21, 22] . Our findings are all the more compelling because the elderly population is rapidly rising [7] . Psaltis and Nicolls [23] pointed out that there is an age paradox with respect to the therapeutic management of elderly patients. Although cardiovascular disease is their major cause of death, they are less studied than their younger counterparts. Indeed, while they account for 1/3 of patients undergoing hospitalization for ACS [24] , they generally constitute b20% of patients included in PCI trials [21] [22] [23] [24] [25] [26] [27] . As a consequence, discordant results have been reported so far. For example, several studies such as XIMA [21] and EXAMINATION [28] and the metaanalysis by Valgimigli et al. [29] failed to demonstrate the superiority of DES compared to BMS in elderly patients, whereas the findings of other trials such as ZEUS and BASKET PROVE as well as several large registries [8, 22, 26, 27, [30] [31] [32] [33] [34] clearly support the benefit of DES.
Despite the DAPT duration of one month only, we observed a very high incidence of major bleeding at one year (Table 2) : one order of magnitude higher than reported in some of the previously published DAPT duration trials [35] [36] [37] . However, it was surprisingly not significantly higher in the elderly patients compared to the younger HBR cohort (7.7% vs. 6.3%) despite their higher CRUSADE score. Additionally, although the major bleeding rate was comparable to that reported in the ANTARTIC trial (7%) [3] which also included patients aged 75 or older presenting with ACS, the ANTARTIC patients received one whole year of DAPT with prasugrel and most LEADERS FREE patients would have presented with an exclusion criterion for ANTARTIC [38] .
It is noteworthy that a large number of cases in the present series were treated via the radial route, which is known to be associated with reduced bleeding and lower mortality, also in elderly patients [39, 40] . Additionally, the use of new potent antiplatelet agents, and GP IIb/IIIa antagonists was particularly low, in both the elderly and younger populations which is to be expected in this high bleeding risk population.
The subgroup of patients included in the trial with age as a sole criterion was relatively small (562 patients, 23.4% of the LEADERS FREE population) and although they had a lower major bleeding rate than the overall elderly group (3% versus 7.3%), it was still higher than many other series of more selected patients on 12 months DAPT, such as RESET (0.6%), EXCELLENT (0.6%) or OPTIMIZE (0.4) [35] [36] [37] . Although the thrombotic event rates with DCS in this subgroup were also comparatively low (MI 6.6 vs. 9.9%, ST 0.7 vs. 2.4%) one could speculate that a more prolonged course of DAPT could have been be justified in some of these patients. Only a randomized trial of different DAPT durations in this group would provide a definitive answer.
Defining elderly patients at those 75 or older may be perceived by some as arbitrary and too broad. It is, however, a standard cut-off in numerous other studies of antiplatelet treatments and is frequently referred to in the guidelines [1] [2] [3] [4] [5] .
As is consistently observed, elderly patients comprised more females, had a higher incidence of AF and were more frequently treated in an acute rather than a stable setting [41] . Even though the elderly had more safety and efficacy events than their younger counterparts, they also had superior outcomes with DCS compared to BMS regardless of age. In general, elderly patients are treated more conservatively in unstable situations, and when undergoing PCI, have frequently received BMS because of their age. The importance of conducting dedicated trials involving the elderly population has recently been underlined in a scientific statement from the AHA/ACC/AGS [1] [6] . Our study addresses one of the knowledge gaps regarding the optimal treatment of the elderly.
Limitations
Although the study group of elderly patients was predefined, the trial was not powered to detect differences in a subgroup of patients 75 years of age or older. Consequently, these very encouraging results can only be regarded as hypothesis-generating.
The findings of the study involve a very specific DCS, namely a polymer-free Biolimus A9 and cannot, therefore, be extrapolated to other DCS or DES.
In addition, the antiplatelet treatment under investigation, i.e. onemonth DAPT followed by SAPT, was the same for both study groups. This precludes any conclusion being drawn regarding the potential outcomes that could have been achieved with different DAPT durations.
Finally, we defined our population using only an age limit criterion. Frailty scores, developed in collaboration with geriatricians, are regarded as more specific than age alone to define patients at increased risk [32] , but none were used in LEADERS FREE.
Conclusion
Patients aged 75 or over account for a majority (63.4%) of HBR patients in the LEADERS FREE trial. These patients constitute a particularly high risk subset with a very high event rate. Similarly to the whole study group, they benefit markedly from DCS treatment, both in terms of safety and efficacy. However, while the efficacy benefit was maintained when age was the sole inclusion criterion, there was only a non-significant trend suggesting a safety benefit of the DCS, and further studies are, therefore, warranted in this sub-group. Overall, our results are of particular importance in a growing population, which is under-represented in trials and has often been treated with bare metal stents despite its high risk profile.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.ijcard.2017.04.079.
